← Leaderboards
Craig T. Jordan
University Of Kentucky
$14,848,921
Attributed
$15,637,636
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,637,636 · 11
VA$0 · 1
By mechanism
R01$8,613,200 · 7
R35$4,886,339 · 1
P50$1,024,137 · 1
T32$702,566 · 1
S10$411,394 · 1
I01$0 · 1
Top collaborators
- Scott D Cramer2 shared
- Daniel A Pollyea2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPropertyRegimenStem Cell PopulationCellsBaseDesignMolecularStem CellsLeukemiaAcute Myelocytic LeukemiaTherapeutic TargetNovel TherapeuticsPathway InteractionsHematopoietic Stem CellsMetabolicIn VivoBiologyRelapseBiologicalPathogenesisNovel StrategiesResistanceGrowth
Grant awards (44)
Therapeutic Targeting of Human AML Stem Cells$921,336
R35 · FY2025 · CA · contact PI
Targeting mitochondrial calcium to eradicate leukemia-initiating cells$437,432
R01 · FY2025 · CA · contact PI
Training Program in Cancer Biology$333,455
T32 · FY2025 · CA · contact PI
Therapeutic Targeting of Human AML Stem Cells$884,768
R35 · FY2024 · CA · contact PI
Targeting mitochondrial calcium to eradicate leukemia-initiating cells$437,432
R01 · FY2024 · CA · contact PI
Training Program in Cancer Biology$369,111
T32 · FY2024 · CA · contact PI
Therapeutic Targeting of Human AML Stem Cells$895,854
R35 · FY2023 · CA · contact PI
Therapeutic Targeting of MDS Stem Cells$0
I01 · FY2023 · VA · contact PI
Therapeutic Targeting of Human AML Stem Cells$912,708
R35 · FY2022 · CA · contact PI
Therapeutic Targeting of MDS Stem Cells$0
I01 · FY2022 · VA · contact PI
Therapeutic Targeting of Human AML Stem Cells$931,335
R35 · FY2021 · CA · contact PI
Therapeutic Targeting of MDS Stem Cells$0
I01 · FY2021 · VA · contact PI
Characterization and targeting of leukemia stem cell metabolism$491,936
R01 · FY2020 · CA · contact PI
Metabolic mechanisms of venetoclax resistance in acute myeloid leukemia stem cells$368,502
R01 · FY2020 · CA · contact PI
Microenvironment-induced metabolic plasticity in leukemia stem cells$355,706
R01 · FY2020 · CA · contact PI
Therapeutic Targeting of Human AML Stem Cells$340,338
R35 · FY2020 · CA · contact PI
Therapeutic Targeting of MDS Stem Cells$0
I01 · FY2020 · VA · contact PI
Characterization and targeting of leukemia stem cell metabolism$477,177
R01 · FY2019 · CA · contact PI
Microenvironment-induced metabolic plasticity in leukemia stem cells$345,034
R01 · FY2019 · CA · contact PI
Characterization and targeting of leukemia stem cell metabolism$491,936
R01 · FY2018 · CA · contact PI
Microenvironment-induced metabolic plasticity in leukemia stem cells$355,706
R01 · FY2018 · CA · contact PI
Characterization and targeting of leukemia stem cell metabolism$491,936
R01 · FY2017 · CA · contact PI
Characterization and targeting of leukemia stem cell metabolism$466,601
R01 · FY2016 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$322,663
R01 · FY2016 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$43,495
R01 · FY2016 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$322,576
R01 · FY2015 · CA · contact PI
ONCOGENE COOPERATIVITY IN LEUKEMIA STEM CELLS$43,485
R01 · FY2015 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$311,892
R01 · FY2014 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$301,353
R01 · FY2013 · CA · contact PI
Oncogene Cooperativity in Leukemia Stem Cells$320,588
R01 · FY2012 · CA · contact PI
P-4: Characterization of Lymphoma-Initiating Cells$211,428
P50 · FY2012 · CA · contact PI
P-4: Characterization of Lymphoma-Initiating Cells$199,855
P50 · FY2011 · CA · contact PI
P-4: Characterization of Lymphoma-Initiating Cells$209,887
P50 · FY2010 · CA · contact PI
Selective in vivo Ablation of Leukemia Stem Cells$292,600
R01 · FY2009 · CA · contact PI
P-4: Characterization of Lymphoma-Initiating Cells$237,315
P50 · FY2009 · CA · contact PI
Selective in vivo Ablation of Leukemia Stem Cells$292,600
R01 · FY2008 · CA · contact PI
P-4: Characterization of Lymphoma-Initiating Cells$165,652
P50 · FY2008 · CA · contact PI
Amnis ImageStream Flow Cytometer$411,394
S10 · FY2007 · RR · contact PI
Selective in vivo Ablation of Leukemia Stem Cells$292,600
R01 · FY2007 · CA · contact PI
Cellular and Molecular Studies of Leukemic Stem Cellss$273,762
R01 · FY2006 · CA · contact PI
Cellular and Molecular Studies of Leukemic Stem Cellss$280,350
R01 · FY2005 · CA
Cellular and Molecular Studies of Leukemic Stem Cellss$280,350
R01 · FY2004 · CA
Cellular and Molecular Studies of Leukemic Stem Cellss$257,744
R01 · FY2003 · CA
Cellular and Molecular Studies of Leukemic Stem Cellss$257,744
R01 · FY2002 · CA